Sodium-glucose co-transporter-2 inhibitors: A paradigm shift in treatment for type 2 diabetes.
Matthews DR., (2024), Diabetes, obesity & metabolism, 26 Suppl 5, 3 - 4
Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis.
Avgerinos I. et al, (2023), Diabetes Obes Metab
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Karagiannis T. et al, (2022), Diabetologia
Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis.
Avgerinos I. et al, (2021), Diabetes Obes Metab
Correction to: Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control.
Tremblay J. et al, (2021), Diabetologia
Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control.
Tremblay J. et al, (2021), Diabetologia
Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis.
Avgerinos I. et al, (2021), Diabetes Obes Metab
Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis.
Tsapas A. et al, (2021), Diabetes Obes Metab
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial.
Yu J. et al, (2021), Cardiovasc Res
Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.
Avgerinos I. et al, (2021), Diabetes Obes Metab, 23, 822 - 831
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes.
Tsapas A. et al, (2021), Ann Intern Med, 174
Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: A subanalysis of the VERIFY study.
Chan JCN. et al, (2021), Diabetes Obes Metab, 23, 245 - 251
Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.
Matthews DR. et al, (2020), Diabetes Obes Metab, 22, 2199 - 2203
Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes.
Matthews D. et al, (2020), Diabetes Ther, 11, 2465 - 2476
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Tsapas A. et al, (2020), Ann Intern Med, 173, 278 - 286
Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.
Katulanda P. et al, (2020), Diabetologia, 63, 1440 - 1452
Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.
Katulanda P. et al, (2020), Diabetologia, 1 - 13
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.
Ohkuma T. et al, (2020), Diabetes Obes Metab, 22, 530 - 539
Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis.
Avgerinos I. et al, (2020), Diabetes Obes Metab, 22, 335 - 345